Nuo Therapeutics, Inc. (AURX)
OTCMKTS · Delayed Price · Currency is USD
1.000
+0.033 (3.38%)
Jun 16, 2026, 9:40 AM EST
Nuo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4.13 | 3.31 | 1.37 | 0.61 | 0.11 | - | |
Revenue Growth (YoY) | 155.81% | 142.72% | 124.34% | 442.12% | - | - |
Cost of Revenue | 1.43 | 1.1 | 0.3 | 0.13 | 0.02 | - |
Gross Profit | 2.7 | 2.22 | 1.06 | 0.48 | 0.09 | - |
Selling, General & Admin | 4.92 | 4.73 | 3.52 | 3.65 | 3.41 | 0.09 |
Operating Expenses | 4.92 | 4.73 | 3.52 | 3.65 | 3.41 | 0.09 |
Operating Income | -2.22 | -2.52 | -2.46 | -3.17 | -3.32 | -0.09 |
Interest Expense | -0.17 | -0 | - | -0 | -0 | - |
Interest & Investment Income | - | - | 0 | - | - | - |
Other Non Operating Income (Expenses) | 0.01 | 0.01 | 0 | - | 0 | - |
EBT Excluding Unusual Items | -2.38 | -2.51 | -2.46 | -3.17 | -3.32 | -0.09 |
Other Unusual Items | - | - | 0.13 | - | 0.15 | - |
Pretax Income | -2.38 | -2.51 | -2.32 | -3.17 | -3.17 | -0.09 |
Net Income | -2.38 | -2.51 | -2.32 | -3.17 | -3.17 | -0.09 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.8 |
Net Income to Common | -2.38 | -2.51 | -2.32 | -3.17 | -3.17 | -0.89 |
Shares Outstanding (Basic) | 48 | 47 | 45 | 42 | 40 | 30 |
Shares Outstanding (Diluted) | 48 | 47 | 45 | 42 | 40 | 30 |
Shares Change (YoY) | 3.50% | 4.16% | 7.95% | 5.19% | 32.03% | 10.93% |
EPS (Basic) | -0.05 | -0.05 | -0.05 | -0.08 | -0.08 | -0.03 |
EPS (Diluted) | -0.05 | -0.05 | -0.05 | -0.08 | -0.08 | -0.03 |
Free Cash Flow | -1.7 | -1.14 | -2.39 | -3.18 | -3.77 | -0.12 |
Free Cash Flow Per Share | -0.04 | -0.02 | -0.05 | -0.07 | -0.09 | -0.00 |
Gross Margin | 65.46% | 66.94% | 77.82% | 79.28% | 82.88% | - |
Operating Margin | -53.69% | -75.95% | -180.04% | -520.65% | -2958.21% | - |
Profit Margin | -57.72% | -75.82% | -170.21% | -521.17% | -2825.60% | - |
Free Cash Flow Margin | -41.07% | -34.40% | -174.82% | -521.76% | -3355.12% | - |
EBITDA | -2.13 | -2.43 | -2.43 | -3.15 | -3.31 | - |
EBITDA Margin | -51.45% | -73.37% | -178.35% | - | - | - |
D&A For EBITDA | 0.09 | 0.09 | 0.02 | 0.02 | 0.01 | - |
EBIT | -2.22 | -2.52 | -2.46 | -3.17 | -3.32 | -0.09 |
EBIT Margin | -53.69% | -75.95% | -180.04% | - | - | - |
Revenue as Reported | 4.13 | 3.31 | 1.37 | 0.61 | 0.11 | - |